Kleinman S, Anton-Guirigis H, Culver B D, Taylor T H, Prince H E, Kaplan H S
Vox Sang. 1986;51(2):143-7. doi: 10.1111/j.1423-0410.1986.tb00231.x.
We have evaluated the western blot (WB) test for distinguishing anti-HTLV III ELISA-positive donors who have likely been exposed to HTLV III from those that are false positives. Of 1,955 donors, 26 were positive for anti-HTLV III by ELISA testing. Only 6 (23%) were positive by WB: 5 of these 6 were male homosexuals with multiple partners and 5 of 6 had low Th/Ts ratios. The WB-positive donors gave the highest absorbance values in the anti-HTLV III ELISA assay. The immunologic abnormalities in the WB-positive donors suggest that they should be notified of their test results. We conclude that basing a donor notification policy on WB results is the optimum public health strategy for blood banks at the present time.
我们评估了蛋白质印迹法（WB）检测，以区分可能接触过人类嗜T淋巴细胞病毒III型（HTLV III）的抗HTLV III酶联免疫吸附测定（ELISA）阳性献血者和假阳性献血者。在1955名献血者中，有26人ELISA检测抗HTLV III呈阳性。只有6人（23%）WB检测呈阳性：这6人中5人为有多个性伴侣的男性同性恋者，6人中有5人Th/Ts比值较低。WB阳性的献血者在抗HTLV III ELISA检测中吸光度值最高。WB阳性献血者的免疫异常表明应告知他们检测结果。我们得出结论，目前基于WB结果制定献血者通知政策是血库最佳的公共卫生策略。
